Men After Prostate Surgery: Sexual Health, ED Recovery, and What to Expect

How Common Is Erectile Dysfunction After Prostate Surgery?

ED after radical prostatectomy (RP) is the most common sexual complication of prostate cancer treatment, reported in 25 to 90 percent of men, with rates driven primarily by whether the cavernous nerves were spared. A landmark prospective study by Alemozaffar et al. published in JAMA (2011, N=1,027) found that only 23.7 percent of men who were potent before surgery reported good erectile function two years after bilateral nerve-sparing RP at a high-volume center. [1] At lower-volume centers without nerve-sparing, rates fall further.

The cavernous nerves run directly along the posterior lateral surface of the prostate. Any stretch, thermal injury, or resection damages those nerves and interrupts the nitric-oxide signaling that initiates an erection. The injury is often neuropraxic, meaning structural continuity is preserved but conduction is impaired, which is why recovery can occur over months rather than being immediate or never.

Pre-operative erectile function is the single strongest predictor of post-operative recovery. [2] Men with excellent pre-operative function who undergo bilateral nerve-sparing RP at high-volume centers have the best prognosis. Age, body mass index, cardiovascular comorbidity, and baseline testosterone each modify that prognosis independently.

Patients should understand that even in optimal circumstances, erectile function at 24 months may not match pre-surgical baseline. The Sexual Health Inventory for Men (SHIM) score drops on average by 10 to 15 points immediately post-surgery in nerve-sparing cases, with partial recovery thereafter. [3]

What Happens to Ejaculation and Orgasm?

Dry orgasm is universal after radical prostatectomy. Removing the prostate eliminates prostatic fluid, and removal or ligation of the seminal vesicles eliminates seminal vesicle secretions, so no semen is produced. [4] This is called anejaculation, not to be confused with anorgasmia. Most men retain the capacity for orgasm, though the sensation often differs from pre-surgical experience.

Climacturia (urinary leakage at orgasm) affects 20 to 93 percent of men in the first year post-surgery, with rates declining over time. [5] A 2014 review in European Urology (Choi et al.) reported climacturia in roughly 45 percent of men at six months, dropping to around 20 percent at 24 months. [5]

Orgasm intensity may decrease in some men. This appears related to loss of prostatic and seminal vesicle contractions that contribute to the orgasmic sensation. Pelvic floor physiotherapy may improve orgasm quality and reduce climacturia by strengthening the rhabdosphincter. [6]

Men should be counseled pre-operatively that anejaculation is permanent. Fertility via sperm banking must occur before surgery if biologic paternity is a future goal.

The Timeline of Erectile Recovery: What the Evidence Shows

Recovery is not linear. Most nerve-sparing patients experience a period of complete erectile dysfunction immediately after surgery, then gradual return of partial function over 12 to 24 months.

The Prostate Cancer Outcomes Study (PCOS), a large population-based cohort, reported that 59.9 percent of men had ED at 18 months post-prostatectomy, declining to 43.5 percent at five years in men who had bilateral nerve-sparing procedures. [7] At non-nerve-sparing centers the five-year ED rate exceeded 70 percent.

Penile hypoxia during the period of nerve-quiescence is a key driver of fibrosis. When cavernous nerves are injured, smooth muscle in the corpora cavernosa is deprived of the trophic nitric oxide signal, leading to collagen deposition and smooth muscle apoptosis. Early pharmacologic rehabilitation targets this mechanism directly. [8]

Starting a PDE5 inhibitor (sildenafil, tadalafil, or vardenafil) within four weeks of surgery, before spontaneous erections return, reduces smooth muscle fibrosis in animal models and has clinical support from randomized trials. The Nightly Penile Rehabilitation (NPR) concept stems from Montorsi et al.'s original 1997 work showing that intracavernosal alprostadil started early improved spontaneous erection recovery at six months compared to no treatment (67% vs. 20%). [9]

Penile Rehabilitation: The Evidence-Based Approaches

Three first-line rehabilitation tools have the most clinical evidence: oral PDE5 inhibitors, vacuum erection devices (VEDs), and intracavernosal injections (ICI).

Oral PDE5 Inhibitors. A 2013 Cochrane review found that nightly low-dose tadalafil (5 mg) significantly improved erectile function scores compared to on-demand dosing in post-prostatectomy patients, with a mean International Index of Erectile Function (IIEF) domain score increase of 3.6 points (95% CI 1.9 to 5.4) over placebo. [10] Nightly tadalafil 5 mg is the most commonly recommended rehabilitation regimen in current AUA guidelines. [11]

Vacuum Erection Devices. VEDs produce a penile erection by creating negative pressure, pulling blood into the corpora. Used daily, they may reduce fibrosis and maintain penile length. Kohler et al. (2007, N=28) showed that men randomized to VED use starting within 30 days of surgery had significantly better IIEF scores and less penile shortening at six months compared to controls. [12]

Intracavernosal Injections. Alprostadil (prostaglandin E1) injected directly into the corpus cavernosum produces erections independent of nerve function. Response rates exceed 80 percent in post-prostatectomy patients. [13] ICI is appropriate when oral PDE5 inhibitors fail or when nerve injury is severe. Starting dose is typically alprostadil 2.5 to 5 mcg, titrated upward under physician supervision. Combination formulas (TriMix: papaverine, phentolamine, alprostadil) offer higher efficacy with lower rates of priapism at lower individual drug doses. [13]

Intraurethral Alprostadil (MUSE). Less effective than ICI in the post-prostatectomy setting, with response rates around 40 to 50 percent in nerve-damaged tissue, but useful for men who prefer to avoid injections. [14]

The HealthRX Penile Rehabilitation Decision Framework (reviewed by our medical team):

1. Begin nightly tadalafil 5 mg within 4 weeks of nerve-sparing RP.
2. Add VED daily sessions (15 to 20 minutes) at week 6 if erections are absent.
3. If IIEF erectile function domain score remains below 17 at month 6, introduce ICI with alprostadil or TriMix.
4. At month 12, reassess for penile prosthesis candidacy if all pharmacologic options have failed.

ED After Prostate Surgery in Men With Diabetes

Men with diabetes face a steeper recovery curve. Diabetic neuropathy and endothelial dysfunction compound cavernous nerve injury from surgery. A retrospective cohort study (Fode et al., BJU International, 2013, N=421) found that diabetic men undergoing nerve-sparing RP had a 30 to 40 percent lower probability of regaining functional erections at 24 months compared to non-diabetic men with equivalent nerve-sparing status. [15]

Glycemic control matters. Each 1-point rise in HbA1c above 7.0% correlates with reduced response to PDE5 inhibitors in men with post-prostatectomy ED. [16] Tight glycemic control during the rehabilitation window is therefore a clinical priority, not an afterthought.

PDE5 inhibitor dosing may need escalation. Men with diabetes often require higher doses of sildenafil (100 mg) or tadalafil (20 mg on-demand) and earlier transition to ICI. Metformin use does not appear to blunt PDE5 inhibitor response, but SGLT-2 inhibitors may offer a secondary benefit through endothelial protection, though this has not been studied specifically in post-prostatectomy diabetic populations. [17]

ED After Prostate Surgery in Men With Heart Disease

Cardiovascular disease shares pathophysiology with ED: endothelial dysfunction, reduced nitric oxide bioavailability, and arterial stiffness all impair cavernosal blood flow. Men with coronary artery disease or heart failure undergoing RP have significantly worse erectile outcomes post-surgery. [18]

The Princeton Consensus (Third) Guidelines state that sexual activity equivalent to climbing two flights of stairs without symptoms is acceptable for most stable cardiac patients. Men who cannot meet that threshold should be cardiac-stabilized before sexual rehabilitation is prioritized. [18]

PDE5 inhibitors are contraindicated with nitrate medications of any kind, including nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate, due to risk of severe hypotension. [11] Men on nitrates requiring post-prostatectomy ED treatment should be referred to a cardiologist to discuss whether nitrate-free windows are feasible or whether alternative ED therapies (VED, ICI) are safer.

Beta-blocker use does not contraindicate PDE5 inhibitors, though metoprolol and carvedilol themselves carry a modest risk of ED that may confound post-surgical recovery. [19] A systematic review in Journal of the American College of Cardiology (Vlachopoulos et al., 2013) confirmed that in stable cardiovascular disease, PDE5 inhibitors are associated with a reduced risk of major cardiovascular events compared to placebo (OR 0.74 to 95% CI 0.56 to 0.98). [20]

Testosterone Replacement Therapy (TRT) After Prostate Surgery

The use of TRT in men after radical prostatectomy for prostate cancer remains one of the more debated questions in urology and endocrinology. Historically, any testosterone exposure after prostate cancer treatment was avoided based on the Huggins androgen-deprivation hypothesis from the 1940s. More recent evidence has modified that stance substantially.

A systematic review by Pastuszak et al. (Journal of Urology, 2013, N=227 across seven studies) found no statistically significant increase in biochemical recurrence in men receiving TRT after RP, with median follow-up of 36 months and PSA remaining stable or undetectable. [21] The "saturation model" (Morgentaler and Traish, 2009) proposes that prostate androgen receptors become saturated at relatively low testosterone concentrations, so supraphysiologic levels do not proportionally stimulate residual prostate cancer cells. [22]

Current practice parameters from most urologists require:

• Undetectable PSA for at least 12 months post-RP (some centers require 24 months for higher Gleason grades).
• Pathologically confirmed organ-confined disease (pT2) or favorable intermediate-risk features.
• Informed consent documenting the limited long-term data.
• PSA monitoring every three months in the first year of TRT, then every six months thereafter.

Testosterone deficiency after prostatectomy is common independent of androgen-deprivation therapy. Surgical stress and pre-existing hypogonadism both contribute. Low testosterone impairs response to PDE5 inhibitors. A 2016 study in BJU International (Khera et al., N=103) found that adding testosterone supplementation to sildenafil in hypogonadal post-prostatectomy men significantly improved IIEF scores compared to sildenafil alone (mean IIEF-EF domain score 16.8 vs. 12.1, P<0.001). [23]

Men on TRT after prostatectomy should not receive TRT concurrently with androgen-deprivation therapy (ADT) used for biochemical recurrence, as these are directly opposing interventions.

Sexual Health After BPH Surgery

Benign prostatic hyperplasia (BPH) requires a different surgical conversation than prostate cancer. The most common procedures (TURP, laser enucleation, Rezum, UroLift) each carry distinct sexual side effect profiles.

TURP (Transurethral Resection of the Prostate). Retrograde ejaculation occurs in 65 to 90 percent of men after TURP because resection of the bladder neck disrupts the internal urethral sphincter's closure during orgasm. [24] New-onset ED occurs in approximately 14 percent of cases, likely due to thermal or electrical injury to cavernous nerve branches running near the prostatic capsule. [24]

HoLEP (Holmium Laser Enucleation of the Prostate). Retrograde ejaculation rates are comparable to TURP (approximately 75 to 80%). New ED rates are lower, reported at 5 to 8 percent in prospective series, attributed to the more precise laser enucleation plane. [25]

Rezum (Water Vapor Therapy). Sexual function is substantially better preserved. A 2019 randomized controlled trial (McVary et al., Journal of Urology, N=197) showed no significant change in IIEF scores at two years and retrograde ejaculation in only 3.8 percent of treated men versus 7.1 percent of control subjects. [26]

UroLift (Prostatic Urethral Lift). Of the common BPH procedures, UroLift has the most favorable sexual function data. The L.I.F.T. trial (Roehrborn et al., 2013, N=206) found no new cases of sustained ED and no cases of retrograde ejaculation attributable to the device at 12 months. [27] Men concerned about preserving ejaculatory function should be offered UroLift or Rezum when anatomy is appropriate (prostate volume generally below 80 mL for UroLift).

Men with BPH who also have ED should be aware that both conditions share the same endothelial and nitric-oxide pathway dysfunction, and that tadalafil 5 mg daily is FDA-approved for both conditions simultaneously, making it a logical first pharmacologic choice post-BPH surgery once surgical healing is confirmed. [28]

Penile Prosthesis: When Rehabilitation Has Been Exhausted

Inflatable penile prosthesis (IPP) implantation is the definitive surgical treatment for ED refractory to pharmacologic rehabilitation. The three-piece IPP (AMS 700 series, Coloplast Titan) achieves patient satisfaction rates of 92 to 98 percent at five years. [29]

The optimal timing for IPP after RP is after the 24-month spontaneous recovery window has passed, assuming adequate pharmacologic rehabilitation was attempted. Early implantation (before 12 months) may foreclose spontaneous nerve recovery. Semirigid rod prostheses are less commonly used but appropriate for men with limited manual dexterity who cannot operate an inflatable device.

A 2015 prospective study (Tal et al., N=82) found that men who underwent IPP implantation within 24 months of failed RP rehabilitation reported equivalent satisfaction scores to men implanted for non-surgical ED, dispelling concern that post-prostatectomy patients are harder to satisfy with prosthesis outcomes. [29]

Prostate cancer surgery does not preclude prosthesis implantation, but prior radiation therapy (external beam or brachytherapy) increases mechanical revision risk by approximately 15 percent compared to surgery-only patients due to pelvic fibrosis and altered tissue planes. [30]

Psychological and Relationship Impact

Sexual dysfunction after prostatectomy extends beyond the physical. Depression, anxiety, and relationship distress are documented in 25 to 40 percent of post-prostatectomy patients and their partners. [31] A prospective cohort study in Cancer (Rosen et al., 2004, N=1,236) found that partner distress was the strongest predictor of a man's sexual dissatisfaction at 12 months post-RP, surpassing erectile function score as a predictor. [31]

Couples-based sex therapy, specifically Sensate Focus therapy adapted for post-surgical couples, has Level II evidence supporting improvement in sexual satisfaction independent of erectile function recovery. [32] Referral to a sexual health psychologist or certified sex therapist should be offered at the three-month post-op visit, not deferred until pharmacologic options are exhausted.

Men should understand that penetrative intercourse is one component of sexual satisfaction. Many post-prostatectomy couples report high overall sexual satisfaction through expanded intimacy approaches even when penetrative function remains impaired. [32]

Pelvic Floor Physical Therapy

Pelvic floor muscle training (PFMT) reduces post-prostatectomy urinary incontinence, but its role in erectile recovery is increasingly recognized. A randomized trial (Dorey et al., BJU International, 2005, N=55) found that men receiving PFMT after RP had significantly higher IIEF scores at six months compared to controls (mean difference 3.7 points, P<0.05). [33] PFMT strengthens the ischiocavernosus and bulbocavernosus muscles, which contribute to rigidity during erection by compressing the deep dorsal vein of the penis.

Referral to a pelvic floor physiotherapist trained in male pelvic dysfunction should occur within the first four to six weeks post-surgery, concurrent with pharmacologic rehabilitation initiation.